Eli Lilly

Scott Galloway: Why I'm selling my American stocks

My First Million

Pharmaceutical company cited alongside Novo Nordisk as a GLP-1 drug supplier; referenced in the same policy discussion.

#133 - Vinay Prasad, M.D., M.P.H: Hallmarks of successful cancer policy

Peter Attia MD

Pharmaceutical company mentioned as an example of industry offering consulting opportunities to junior faculty, creating potential conflicts of interest.

E150: Israel/Gaza escalating or not? EU censorship regime, Penn donors revolt, GLP-1 hype cycle

All-In Podcast

Pharmaceutical company mentioned as a winner in the GLP-1 market hype cycle.

The All-In Holiday Spectacular

All-In Podcast

David Ricks, its CEO, is recognized for building a billion-dollar company and being unstoppable.

The Science of Hunger & Medications to Combat Obesity | Dr. Zachary Knight

Andrew Huberman

The pharmaceutical company that makes the GLP-1/GIP dual agonist tirzepatide (Mounjaro/Zepbound) and is developing a triple agonist.

Howard Marks on the US Dollar, Three Ways to Add Defense, and Good Questions | The Tim Ferriss Show

Tim Ferriss

A 'Nifty 50' company cited as an example of growth stocks that, despite their quality, suffered significant declines due to high initial prices.

Big Pharma and the Big Lie – The Chemical Imbalance Theory of Mental Illness

Academy of Ideas

Markets turn Trump, Long rates spike, Election home stretch, Influencer mania, Saving Starbucks

All-In Podcast

A pharmaceutical company whose stock performance (representing anti-sugar trends) is compared positively against Starbucks, suggesting a market shift towards health.

Dave Ricks, CEO of Eli Lilly | The All-In Interview

All-In Podcast

A pharmaceutical company discussed as the world's most valuable, leading the GLP-1 drug market, and experiencing significant growth in market cap and revenue.